Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Li-Li Peng, Yan Li, Ming-An Yu
{"title":"手术或消融治疗后甲状旁腺功能亢进症持续/复发患者的微波消融并发症。","authors":"Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Li-Li Peng, Yan Li, Ming-An Yu","doi":"10.1080/02656736.2024.2308063","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the complications associated with microwave ablation (MWA) in treating persistent/recurrent hyperparathyroidism (HPT) post-surgical or ablative treatments.</p><p><strong>Materials and methods: </strong>From January 2015 to December 2022, 87 persistent/recurrent HPT patients (primary HPT [PHPT]: secondary HPT [SHPT] = 13:74) who underwent MWA after surgical or ablative treatment were studied. Grouping was based on ablation order (initial vs. re-MWA), prior treatment (parathyroidectomy [PTX] vs. MWA), and etiology (PHPT vs. SHPT). The study focused on documenting and comparing treatment complications and analyzing major complication risk factors.</p><p><strong>Result: </strong>Among the 87 patients, the overall complication rate was 17.6% (15/87), with major complications at 13.8% (12/87) and minor complications at 3.4% (3/87). Major complications included recurrent laryngeal nerve (RLN) palsy (12.6%) and Horner syndrome (1.1%), while minor complications were limited to hematoma (3.4%). Severe hypocalcemia noted in 21.6% of SHPT patients. No significant differences in major complication rates were observed between initial and re-MWA groups (10.7% vs. 13.8%, <i>p</i> = 0.455), PTX and MWA groups (12.5% vs. 15.4%, <i>p</i> = 0.770), or PHPT and SHPT groups (15.4% vs. 13.5%, <i>p</i> > 0.999). Risk factors for RLN palsy included ablation of superior and large parathyroid glands (>1.7 cm). All patients recovered spontaneously except for one with permanent RLN palsy in the PTX group (2.1%).</p><p><strong>Conclusion: </strong>Complication rates for MWA post-surgical or ablative treatments were comparable to initial MWA rates. Most complications were transient, indicating MWA as a viable and safe treatment option for persistent/recurrent HPT patients.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":"41 1","pages":"2308063"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complications of microwave ablation in patients with persistent/recurrent hyperparathyroidism after surgical or ablative treatment.\",\"authors\":\"Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Li-Li Peng, Yan Li, Ming-An Yu\",\"doi\":\"10.1080/02656736.2024.2308063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the complications associated with microwave ablation (MWA) in treating persistent/recurrent hyperparathyroidism (HPT) post-surgical or ablative treatments.</p><p><strong>Materials and methods: </strong>From January 2015 to December 2022, 87 persistent/recurrent HPT patients (primary HPT [PHPT]: secondary HPT [SHPT] = 13:74) who underwent MWA after surgical or ablative treatment were studied. Grouping was based on ablation order (initial vs. re-MWA), prior treatment (parathyroidectomy [PTX] vs. MWA), and etiology (PHPT vs. SHPT). The study focused on documenting and comparing treatment complications and analyzing major complication risk factors.</p><p><strong>Result: </strong>Among the 87 patients, the overall complication rate was 17.6% (15/87), with major complications at 13.8% (12/87) and minor complications at 3.4% (3/87). Major complications included recurrent laryngeal nerve (RLN) palsy (12.6%) and Horner syndrome (1.1%), while minor complications were limited to hematoma (3.4%). Severe hypocalcemia noted in 21.6% of SHPT patients. No significant differences in major complication rates were observed between initial and re-MWA groups (10.7% vs. 13.8%, <i>p</i> = 0.455), PTX and MWA groups (12.5% vs. 15.4%, <i>p</i> = 0.770), or PHPT and SHPT groups (15.4% vs. 13.5%, <i>p</i> > 0.999). Risk factors for RLN palsy included ablation of superior and large parathyroid glands (>1.7 cm). All patients recovered spontaneously except for one with permanent RLN palsy in the PTX group (2.1%).</p><p><strong>Conclusion: </strong>Complication rates for MWA post-surgical or ablative treatments were comparable to initial MWA rates. Most complications were transient, indicating MWA as a viable and safe treatment option for persistent/recurrent HPT patients.</p>\",\"PeriodicalId\":14137,\"journal\":{\"name\":\"International Journal of Hyperthermia\",\"volume\":\"41 1\",\"pages\":\"2308063\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hyperthermia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02656736.2024.2308063\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hyperthermia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02656736.2024.2308063","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:评估微波消融治疗甲状旁腺功能亢进症(HPT)的并发症:评估微波消融术(MWA)治疗手术或消融治疗后顽固性/复发性甲状旁腺功能亢进症(HPT)的相关并发症:从2015年1月至2022年12月,对87名在手术或消融治疗后接受微波消融术的顽固性/复发性甲状旁腺功能亢进症患者(原发性甲状旁腺功能亢进症[PHPT]:继发性甲状旁腺功能亢进症[SHPT]=13:74)进行了研究。根据消融顺序(初次与再次MWA)、先前治疗(甲状旁腺切除术 [PTX] 与 MWA)和病因(PHPT 与 SHPT)进行分组。研究重点是记录和比较治疗并发症,分析主要并发症风险因素:87名患者中,总并发症发生率为17.6%(15/87),其中主要并发症为13.8%(12/87),次要并发症为3.4%(3/87)。主要并发症包括喉返神经(RLN)麻痹(12.6%)和霍纳综合征(1.1%),而轻微并发症仅限于血肿(3.4%)。21.6%的 SHPT 患者出现严重低钙血症。初次和再次MWA组(10.7% vs. 13.8%,P = 0.455)、PTX和MWA组(12.5% vs. 15.4%,P = 0.770)或PHPT和SHPT组(15.4% vs. 13.5%,P > 0.999)之间的主要并发症发生率无明显差异。RLN麻痹的风险因素包括上甲状旁腺和大甲状旁腺(>1.7厘米)的消融。除了PTX组的一名永久性RLN麻痹患者(2.1%)外,所有患者均可自行康复:结论:手术或消融治疗后的MWA并发症发生率与最初的MWA发生率相当。大多数并发症都是一过性的,这表明 MWA 是针对顽固性/复发性 HPT 患者的一种可行且安全的治疗方案。
Complications of microwave ablation in patients with persistent/recurrent hyperparathyroidism after surgical or ablative treatment.
Objective: To evaluate the complications associated with microwave ablation (MWA) in treating persistent/recurrent hyperparathyroidism (HPT) post-surgical or ablative treatments.
Materials and methods: From January 2015 to December 2022, 87 persistent/recurrent HPT patients (primary HPT [PHPT]: secondary HPT [SHPT] = 13:74) who underwent MWA after surgical or ablative treatment were studied. Grouping was based on ablation order (initial vs. re-MWA), prior treatment (parathyroidectomy [PTX] vs. MWA), and etiology (PHPT vs. SHPT). The study focused on documenting and comparing treatment complications and analyzing major complication risk factors.
Result: Among the 87 patients, the overall complication rate was 17.6% (15/87), with major complications at 13.8% (12/87) and minor complications at 3.4% (3/87). Major complications included recurrent laryngeal nerve (RLN) palsy (12.6%) and Horner syndrome (1.1%), while minor complications were limited to hematoma (3.4%). Severe hypocalcemia noted in 21.6% of SHPT patients. No significant differences in major complication rates were observed between initial and re-MWA groups (10.7% vs. 13.8%, p = 0.455), PTX and MWA groups (12.5% vs. 15.4%, p = 0.770), or PHPT and SHPT groups (15.4% vs. 13.5%, p > 0.999). Risk factors for RLN palsy included ablation of superior and large parathyroid glands (>1.7 cm). All patients recovered spontaneously except for one with permanent RLN palsy in the PTX group (2.1%).
Conclusion: Complication rates for MWA post-surgical or ablative treatments were comparable to initial MWA rates. Most complications were transient, indicating MWA as a viable and safe treatment option for persistent/recurrent HPT patients.